Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × pembrolizumab × CNS × Clear all

Phase

Phase 2 38 Phase 1 18 Phase 1/2 15 Phase 3 3 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Head & Neck 2 Tumor-Agnostic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Glioblastoma 1

Interventions

Saline Solution 6 Dexmedetomidine 5 Sodium Chloride 4 Sevoflurane 3 Propofol 3 Levetiracetam 3 trametinib 2 perampanel 2 dabrafenib 2 Temozolomide 2 Sugammadex 2 Methylphenidate 2 Magnetic Resonance Spectroscopy 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 Gentamicins 2 Fluorescein 2 Anesthesia, Inhalation 2 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 pembrolizumab 1 pegvisomant 1 naxitamab 1 lorlatinib 1 gadoterate meglumine 1 gadobenic acid 1 dexketoprofen trometamol 1 clevidipine 1 Vincristine 1 Valproic Acid 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05235737 2023-08-31

PIRG

Medical University of Silesia

Phase 4 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡